ClinicalTrials.gg
CompletedNCT04713592IMMprintUpdated Jun 14, 2024Results posted

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

A Phase 3 interventional study of Placebo for Risankizumab and Risankizumab in Psoriasis, sponsored by AbbVie. Completed at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
14th of 30
174 · median 162
Started
2021
with 4 others
Phase 3
17 of 30
none open now
Registered
23rd of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 14th largest by enrollment, is one of 5 that started in 2021, is one of 17 in phase 3, and was the 23rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Palmoplantar (non-pustular) plaque psoriasis (PPPsO) represents a localized form of psoriasis in palms and soles. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis with palmoplantar involvement and to assess change in disease symptoms.

Risankizumab is an approved drug for the treatment of psoriasis. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo in Period A. In Period B, all the participants will receive risankizumab. Around 168 adult participants with a moderate to severe plaque psoriasis will be enrolled in approximately 55 sites across the world.

Participants will receive single subcutaneous (administered under the skin) risankizumab or placebo in period A (16 weeks). In period B (36 weeks), all participants will receive subcutaneous risankizumab once every 12 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Psoriasis

Keywords

  • Psoriasis
  • Plaque Psoriasis
  • Moderate to Severe Plaque Psoriasis
  • Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO)
  • Risankizumab
  • SKYRIZI
  • ABBV-066
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic palmoplantar plaque psoriasis (PPPsO) (with or without psoriatic arthritis) for at least 6 months before Baseline and a Palmoplantar Investigator's Global Assessment (ppIGA) of moderate or severe, at Screening and Baseline.
  • Must have at Screening and Baseline a plaque psoriasis (PsO) body surface area (BSA) involvement of greater than or equal to one percent, an Static Physician's Global Assessment (sPGA) score of moderate to severe (greater than or equal to three), a PPASI moderate to severe (greater than or equal to eight), at least one additional PsO plaque outside of the palms and soles.
  • Must be a candidate for systemic therapy as assessed by the investigator.
  • Previously had inadequately controlled disease by topicals, phototherapy and/or systemic treatments.

Exclusion criteria

Exclusion Criteria:

  • History of PsO other than chronic plaque type PsO
  • History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.
  • Ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with PsO assessments.
  • Evidence of virus (HBV) or virus (HCV) infection, (HIV), Active tuberculosis, Active systemic infection/ infections in the last two weeks prior to Baseline.
  • Prior exposure to risankizumab.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
174 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received subcutaneous placebo injections during the 16-week Double-blind Period at Baseline (Day 1) and Week 4. Starting at Week 16, all participants received open-label risankizumab 150 mg subcutaneous injections once every 12 weeks (q12w) at Weeks 16, 28, and 40.

    Drug: Placebo for Risankizumab · Drug: Risankizumab

  • Experimental
    Risankizumab

    Participants received risankizumab 150 mg subcutaneous injections during the 16-week Double-blind Period at Baseline (Day 1) and Week 4. Starting at Week 16, all participants received open-label risankizumab 150 mg subcutaneous injections once every 12 weeks (q12w) at Weeks 16, 28, and 40.

    Drug: Risankizumab

Interventions

  • DrugPlacebo for Risankizumab

    Subcutaneous (SC) Injection

  • Subcutaneous (SC) Injection

    Also known as: ABBV-066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16

    The ppIGA is a 5-point score ranging from 0 to 4, based on the investigator's assessment of the average erythema (redness), induration (thickness), and scaling of all palmoplantar (non-pustular) psoriatic lesions. A lower score indicates lower severity, with 0 being "clear" and 1 being "almost clear."

    Time frame: Baseline, Week 16

  2. Number of Participants With Treatment-Emergent Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From the first dose of study drug in the Double-blind Period up to 140 days after the last dose; from the first dose of study drug in the Open-label Period up to 140 days after the last dose and the end of study date (up to 60 weeks)

Secondary outcomes

  1. Percentage of Participants Achieving ≥ 75% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) Response at Week 16

    PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72. Higher scores indicate more severe disease.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving ≥ 90% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) Response at Week 16

    PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72. Higher scores indicate more severe disease.

    Time frame: Baseline, Week 16

  3. Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16

    sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Higher scores indicate more severe disease.

    Time frame: Baseline, Week 16

  4. Percentage of Participants Achieving 100% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) Response at Week 16

    PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72. Higher scores indicate more severe disease.

    Time frame: Baseline, Week 16

07

Results

Posted Jun 14, 2024

Participant flow

Double-blind Period (Baseline - Week 16)
Participant flow — Double-blind Period (Baseline - Week 16)
MilestonePlaceboRisankizumabPlacebo/RisankizumabRisankizumab/Risankizumab
Started878700
Completed818400
Not completed6300
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject6200
Open-label Period (Week 16 - Week 52)
Participant flow — Open-label Period (Week 16 - Week 52)
MilestonePlaceboRisankizumabPlacebo/RisankizumabRisankizumab/Risankizumab
Started008184
Entered open-label period and received study drug008181
Completed005961
Not completed002223
Withdrew: Adverse event0012
Withdrew: Withdrawal by subject0035
Withdrew: Lost to follow-up0011
Withdrew: Lack of efficacy0011
Withdrew: Other, not specified001614

Outcome measures

PrimaryPercentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16

The ppIGA is a 5-point score ranging from 0 to 4, based on the investigator's assessment of the average erythema (redness), induration (thickness), and scaling of all palmoplantar (non-pustular) psoriatic lesions. A lower score indicates lower severity, with 0 being "clear" and 1 being "almost clear."

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 1616.1 (8.4 to 23.8)33.3 (23.4 to 43.2)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = =0.006 (P-value based on Cochran-Mantel-Haenszel (CMH) test adjusted for Baseline ppIGA and Baseline BSA categories for comparison of treatment groups based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19.) · Rate difference: 17.2 · 95% CI 5.0 to 29.3Difference: Risankizumab - Placebo
PrimaryNumber of Participants With Treatment-Emergent Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From the first dose of study drug in the Double-blind Period up to 140 days after the last dose; from the first dose of study drug in the Open-label Period up to 140 days after the last dose and the end of study date (up to 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsPlaceboRisankizumabPlacebo/RisankizumabRisankizumab/Risankizumab
Any TEAE20252940
TESAE0505
SecondaryPercentage of Participants Achieving ≥ 75% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) Response at Week 16

PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72. Higher scores indicate more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥ 75% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) Response at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving ≥ 75% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) Response at Week 1614.9 (7.5 to 22.4)42.5 (32.1 to 52.9)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (P-value based on Cochran-Mantel-Haenszel (CMH) test adjusted for Baseline ppIGA and Baseline BSA categories for comparison of treatment groups based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19.) · Rate difference: 27.6 · 95% CI 15.4 to 39.7Difference: Risankizumab - Placebo
SecondaryPercentage of Participants Achieving ≥ 90% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) Response at Week 16

PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72. Higher scores indicate more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥ 90% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) Response at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving ≥ 90% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) Response at Week 165.7 (0.9 to 10.6)27.6 (18.2 to 37.0)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (P-value based on Cochran-Mantel-Haenszel (CMH) test adjusted for Baseline ppIGA and Baseline BSA categories for comparison of treatment groups based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19.) · Rate difference: 21.8 · 95% CI 11.5 to 32.1Difference: Risankizumab - Placebo
SecondaryPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16

sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Higher scores indicate more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 1611.5 (4.8 to 18.2)32.2 (22.4 to 42.0)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (P-value based on Cochran-Mantel-Haenszel (CMH) test adjusted for Baseline ppIGA and Baseline BSA categories for comparison of treatment groups based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19.) · Rate difference: 20.7 · 95% CI 9.1 to 32.2Difference: Risankizumab - Placebo
SecondaryPercentage of Participants Achieving 100% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) Response at Week 16

PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72. Higher scores indicate more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 100% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) Response at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving 100% Improvement From Baseline in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) Response at Week 161.1 (0.0 to 3.4)17.2 (9.3 to 25.2)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (P-value based on Cochran-Mantel-Haenszel (CMH) test adjusted for Baseline ppIGA and Baseline BSA categories for comparison of treatment groups based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19.) · Rate difference: 16.2 · 95% CI 8.2 to 24.3Difference: Risankizumab - Placebo

Adverse events

Collected over All-cause mortality and adverse events based on Intent-to-Treat (ITT) during the two study periods from the time of informed consent. Those randomized to Placebo in the Double-blind Period who didn't continue into the Open-label Period weren't included in Open-label Period ITT population. Median time on follow-up was 112 days for placebo and risankizumab groups during the Double-blind Period and 309 days for placebo/risankizumab and risankizumab/risankizumab groups during the Open-label Period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double-blind Period)0/87 (0%)0/87 (0%)2/87 (2.3%)
Risankizumab (Double-blind Period)0/87 (0%)5/87 (5.7%)2/87 (2.3%)
Placebo/Risankizumab (Open-label Period)0/81 (0%)0/81 (0%)8/81 (9.9%)
Risankizumab/Risankizumab (Open-label Period)1/84 (1.2%)5/84 (6%)12/84 (14.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo (Double-blind Period)Risankizumab (Double-blind Period)Placebo/Risankizumab (Open-label Period)Risankizumab/Risankizumab (Open-label Period)
CARDIAC FAILURE CONGESTIVECardiac disorders0/870/870/811/84
MYOCARDIAL INFARCTIONCardiac disorders0/871/870/811/84
CHEST PAINGeneral disorders0/871/870/811/84
COVID-19 PNEUMONIAInfections and infestations0/870/870/811/84
TENDON RUPTUREInjury, poisoning and procedural complications0/870/870/811/84
SYNCOPENervous system disorders0/870/870/811/84
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/870/870/811/84
ANGINA UNSTABLECardiac disorders0/871/870/810/84
CORONARY ARTERY DISEASECardiac disorders0/871/870/810/84
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/871/870/810/84
Most frequent other events
Most frequent other events
EventPlacebo (Double-blind Period)Risankizumab (Double-blind Period)Placebo/Risankizumab (Open-label Period)Risankizumab/Risankizumab (Open-label Period)
COVID-19Infections and infestations2/872/878/8112/84

Baseline characteristics

Intent to Treat Population: all randomized participants, analyzed according to the treatment groups to which they were randomized during the Double-blind Period

Age, Continuous
Age, Continuous(years)PlaceboRisankizumabTotal
Mean53.9 ± 14.3056.9 ± 12.9355.4 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRisankizumabTotal
Female454085
Male424789
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRisankizumabTotal
Hispanic or Latino252853
Not Hispanic or Latino6259121
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRisankizumabTotal
American Indian or Alaska Native112
Asian5914
Native Hawaiian or Other Pacific Islander101
Black or African American639
White7474148
More than one race000
Unknown or Not Reported000
Baseline ppIGA score
Baseline ppIGA score(Participants)PlaceboRisankizumabTotal
Clear000
Almost Clear000
Mild000
Moderate6867135
Severe192039
Baseline PPASI score
Baseline PPASI score(units on a scale)PlaceboRisankizumabTotal
Mean22.46 ± 12.14122.48 ± 13.64722.47 ± 12.878
Baseline sPGA score
Baseline sPGA score(Participants)PlaceboRisankizumabTotal
Clear000
Almost Clear000
Mild000
Moderate7577152
Severe121022
08

Study locations

55 sites
  • Advanced Research Associates - Glendale /ID# 219197
    Glendale, Arizona 85308, United States
  • Burke Pharmaceutical Research /ID# 223349
    Hot Springs, Arkansas 71913-6404, United States
  • NW Arkansas Clinical Trials Center /ID# 231602
    Rogers, Arkansas 72758, United States
  • Dermatology Research Associates /ID# 219195
    Los Angeles, California 90045, United States
  • Integrative Skin Science and Research /ID# 219216
    Sacramento, California 95815, United States
  • Medderm Associates /ID# 219210
    San Diego, California 92103, United States
  • Colorado Center for Dermatology, PLLC /ID# 219223
    Centennial, Colorado 80111-1724, United States
  • Skin Care Research - Hollywood /ID# 219184
    Hollywood, Florida 33021-6748, United States
  • GSI Clinical Research, LLC /ID# 219175
    Margate, Florida 33063, United States
  • Savin Medical Group, LLC /ID# 227754
    Miami Lakes, Florida 33014-2490, United States
  • Lenus Research & Medical Group /ID# 219202
    Sweetwater, Florida 33172, United States
  • Hamilton Research, LLC /ID# 219224
    Alpharetta, Georgia 30022, United States
  • Arlington Dermatology /ID# 219211
    Rolling Meadows, Illinois 60008, United States
  • Northshore University Health System Dermatology Clinical Trials Unit /ID# 219220
    Skokie, Illinois 60077, United States
  • Dawes Fretzin, LLC /ID# 219219
    Indianapolis, Indiana 46256, United States
  • The Dermatology Center PSC - New Albany /ID# 219183
    New Albany, Indiana 47150, United States
  • Epiphany Dermatology of Kansas LLC /ID# 219208
    Overland Park, Kansas 66210, United States
  • Allcutis Research LLC /ID# 222272
    Methuen, Massachusetts 01844-5864, United States
  • David Fivenson, MD, PLC /ID# 219180
    Ann Arbor, Michigan 48103, United States
  • Henry Ford Medical Center /ID# 219205
    Detroit, Michigan 48202-3046, United States
  • Advanced Dermatology of the Midlands /ID# 219207
    Omaha, Nebraska 68144-1105, United States
  • Psoriasis Treatment Center of Central New Jersey /ID# 219201
    East Windsor, New Jersey 08520, United States
  • Forest Hills Dermatology Group /ID# 219200
    Kew Gardens, New York 11415, United States
  • Icahn School of Medicine at Mount Sinai /ID# 219206
    New York, New York 10029-6504, United States
  • ClinOhio Research Services /ID# 222298
    Columbus, Ohio 43213-4440, United States
  • University of Pittsburgh MC /ID# 219203
    Pittsburgh, Pennsylvania 15260, United States
  • Velocity Clinical Research-Providence /ID# 223350
    East Greenwich, Rhode Island 02818, United States
  • Palmetto Clinical Trial Services /ID# 222275
    Fountain Inn, South Carolina 29644-1928, United States
  • Palmetto Clinical Trial Services /ID# 222299
    Fountain Inn, South Carolina 29644-1928, United States
  • International Clinical Research - Tennessee LLC /ID# 220930
    Murfreesboro, Tennessee 37130-2450, United States
  • Menter Dermatology Res Inst /ID# 219161
    Dallas, Texas 75246, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 219221
    Houston, Texas 77004-8097, United States
  • Advanced Clinical Research - Woseth Dermatology /ID# 224750
    Salt Lake City, Utah 84117-4209, United States
  • Virginia Clinical Research, Inc. /ID# 219181
    Norfolk, Virginia 23507, United States
  • Beacon Dermatology Inc /ID# 220940
    Calgary, Alberta T3E 0B2, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 220941
    Surrey, British Columbia V3R 6A7, Canada
  • Dr. Irina Turchin PC Inc. /ID# 220938
    Fredericton, New Brunswick E3B 1G9, Canada
  • NewLab Clinical Research Inc. /ID# 220934
    St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • Dr. S.K. Siddha Medicine Professional Corporation /ID# 220936
    Newmarket, Ontario L3Y 5G8, Canada
  • Research Toronto /ID# 220939
    Toronto, Ontario M4W 2N4, Canada
  • Innovaderm Research Inc. /ID# 222126
    Montréal, Quebec H2X 2V1, Canada
  • Centre de Recherche dermatologique du Quebec Metropolitain /ID# 220935
    Québec, Quebec G1V 4X7, Canada
  • Dr. Samuel Sanchez PSC /ID# 218789
    Caguas, 00727, Puerto Rico
  • Alma M. Cruz Santana, MD-Private practice /ID# 218790
    Carolina, 00985, Puerto Rico
  • Pan American Center for Oncology Trials, LLC /ID# 218788
    Rio Piedras, 00935, Puerto Rico
  • Clinical Research Puerto Rico /ID# 218787
    San Juan, 00909, Puerto Rico
  • GCM Medical Group, PSC /ID# 218786
    San Juan, 00917, Puerto Rico
  • Hospital Universitario Basurto /ID# 220904
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitario de la Princesa /ID# 224911
    Madrid, 28006, Spain
  • Hospital Universitario Ramon y Cajal /ID# 220908
    Madrid, 28034, Spain
  • Hospital Regional Universitario de Malaga /ID# 220900
    Malaga, 29011, Spain
  • Hospital Universitario Virgen del Rocio /ID# 220907
    Sevilla, 41013, Spain
  • Hospital General Universitario de Valencia /ID# 220898
    Valencia, 46014, Spain
  • Hospital Universitario y Politecnico La Fe /ID# 220903
    Valencia, 46026, Spain
  • Hospital Clinico Universitario Lozano Blesa /ID# 222492
    Zaragoza, 50009, Spain
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2023, 25 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 19, 2021
StartActual
Feb 26, 2021
Primary completionActual
Apr 20, 2023
CompletionActual
Apr 20, 2023
Results first posted
Jun 14, 2024
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04713592
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Feb 26, 2021
Primary completion
Apr 20, 2023
Completion
Apr 20, 2023
Results posted
Jun 14, 2024
Last update
Jun 14, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion